GleamWall
中文EN

BMEA Biomea Fusion, Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1840439 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY76.7%
TTM EPS YoY95.8%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-192.3%
ROA-53.6%
ROIC (approx.)—
Asset turnover—

Leverage & solvency

Liabilities / assets73.0%
Debt / equity0.00x
Current ratio2.17x
Interest coverage—

Cash quality & payout

Operating cash flow / net income1.98x
Accruals ratio52.3%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31
Income statement
Revenue——
R&D expense$61.98M$118.08M
SG&A expense$19.33M$25.98M
Operating income-$83.51M-$144.07M
Income tax$0$0
Net income-$61.80M-$138.43M
EBITDA-$82.10M-$142.32M
EPS (basic)-1.18-3.83
EPS (diluted)-1.18-3.83
Weighted avg. shares (diluted)52.23M36.11M
Banking
Net interest income$1.86M$5.64M
Balance sheet
Cash & equivalents$55.81M$58.65M
Current assets$58.05M$68.33M
PP&E, net$153,000$3.77M
Total assets$58.57M$79.94M
Current liabilities$11.10M$21.67M
Total liabilities$29.02M$28.36M
Shareholders' equity$29.55M$51.57M
Shares outstanding72.30M36.31M
Cash flow statement
Operating cash flow-$70.37M-$119.89M
Capital expenditure—$362,000
Free cash flow—-$120.26M
Investing cash flow—-$362,000
Financing cash flow$67.90M$1.67M
Depreciation & amortization$1.41M$1.75M
Stock-based compensation$9.52M$19.09M

Free plan shows the latest 2 periods; Pro shows all 7 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.